Break it Down: Invion completes six patient dosings in cancer trial

Invion has completed the dosing of six patients in its Phase I/II clinical trial for INV-043, treating non-melanoma skin cancers.

Break it down: Invion

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Tylah Tully breaks down the latest scoop from Invion (ASX:IVX), which has achieved a major milestone in its Phase I/II clinical trial for INV-043.

Invion has completed the dosing of six patients, triggering a review from the Safety Review Committee, and ultimately paving the way for the next stage in the trial for non-melanoma skin cancers. 

Originally published as Break it Down: Invion completes six patient dosings in cancer trial